Baseline history of patients using selexipag for pulmonary arterial hypertension
Introduction: Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary a...
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
SAGE Publishing
2019-04-01
|
| Seri Bilgileri: | Therapeutic Advances in Respiratory Disease |
| Online Erişim: | https://doi.org/10.1177/1753466619843774 |